My life & career
Potential medical, food and materials benefits begin as hypotheses that still need careful testing.
YOTTABIT / THE BIG STORIES / Convergence
What if biology, AI and robotics shared a single discovery loop?
Imagine a computer suggesting a biological design, automated instruments testing it, and the results improving the next model. These systems could increasingly work as connected partners in science.
THE BIG PICTURE
This is one of the most intriguing examples of convergence: knowledge, experimentation and physical action beginning to reinforce one another. Research could move through more cycles in the same time.
Biology and medicine still demand rigorous validation. A faster research loop is not equivalent to a faster approved therapy.
THE YOTTABIT PERSPECTIVE
What does it mean to me?
Big change is fascinating. Its implications are what matter.
My business
Build teams that can connect computation, experimentation and operational know-how.
My industry
Biology, automation and computation may create new service models across pharmaceuticals, agriculture and manufacturing.
FROM JIM CARROLL’S WORK
Jim’s convergence keynotes explore how scientific and industrial boundaries become less meaningful when disciplines connect.
Meet the futurist behind YottaBit ↗WHAT COULD I DO MONDAY MORNING?
Find two groups in your organization that rarely collaborate but share a common research bottleneck.
CURIOUS FOR MORE?
Explore the story behind the story.
For those who want the deeper explanation, the research is always available. The fascinating possibilities are only the beginning.
Research, explanations and sources EXPLORE THE DETAILS +
An emerging research system
Imagine a workflow in which a model proposes a protein or genetic hypothesis, laboratory instruments test it, automated equipment generates reliable measurements, and future models learn from those measurements. Pieces of this workflow exist today, but their complete integration and reliable economic value vary by application.
What has already changed
Sequence production is dramatically cheaper; protein-structure databases are enormous; researchers use predictive models and automated instruments. A regulated CRISPR-based therapy was approved for specific indications in 2023. Each is meaningful on its own, but none proves that autonomous medicine is now routine.
The barrier is proof
Success must survive biochemical variability, reproducibility, manufacturing cost, clinical safety, access and regulation. The research question is whether cross-domain systems can reduce cost and time per validated useful outcome.